
When the US Food and Drug Administration approved Makena, a branded formulation of the synthetic progesterone 17 alpha-hydroxyprogesterone caproate on Feb. 4, obstetricians and maternal-fetal medicine specialists celebrated a perceived victory in the fight to reduce premature births.